Edition:
United Kingdom

Horizon Pharma PLC (HZNP.OQ)

HZNP.OQ on NASDAQ Stock Exchange Global Select Market

17.75USD
4:04pm BST
Change (% chg)

$0.18 (+1.02%)
Prev Close
$17.57
Open
$17.57
Day's High
$18.04
Day's Low
$17.57
Volume
138,565
Avg. Vol
527,103
52-wk High
$18.10
52-wk Low
$10.34

Chart for

About

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary... (more)

Overall

Beta: 1.31
Market Cap(Mil.): $2,211.82
Shares Outstanding(Mil.): 163.35
Dividend: --
Yield (%): --

Financials

  HZNP.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -2.69 -- --
ROI: -13.86 14.84 14.38
ROE: -36.88 16.34 16.07

BRIEF-Horizon Pharma Q1 Non-Gaap Earnings Per Share $0.03

* REPORTS STRONG FIRST-QUARTER 2018 ORPHAN AND RHEUMATOLOGY NET SALES GROWTH; INCREASES FULL-YEAR 2018 GUIDANCE AND ANNOUNCES NEW COMPANY OPERATING STRUCTURE TO ENHANCE FOCUS ON RARE DISEASES

09 May 2018

BRIEF-AGC Biologics Enters Commercial Manufacturing Agreement With Horizon Pharma

* AGC BIOLOGICS SAYS ENTERS INTO COMMERCIAL MANUFACTURING AGREEMENT WITH HORIZON PHARMA PLC FOR COMMERCIAL SUPPLY OF TEPROTUMUMAB Source text for Eikon: Further company coverage:

03 May 2018

BRIEF-Horizon Pharma PLC Announces Q4 Non-Gaap Earnings Per Share $0.29

* ‍FULL-YEAR 2018 ADJUSTED EBITDA GUIDANCE OF $370 MILLION TO $395 MILLION​

28 Feb 2018

BRIEF-Horizon Pharma PLC Submits Supplemental NDA For Ravicti

* HORIZON PHARMA PLC SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR RAVICTI® (GLYCEROL PHENYLBUTYRATE) ORAL LIQUID TO EXPAND AGE RANGE TO INCLUDE NEWBORNS Source text for Eikon: Further company coverage:

27 Feb 2018

BRIEF-Paulson & Co Inc UPS SHARE STAKE IN HORIZON PHARMA PLC, CAESARS ENTERTAINMENT CORP

* PAULSON & CO INC TAKES SHARE STAKE OF 2 MILLION SHARES IN CENTURYLINK INC - SEC FILING‍​

14 Feb 2018

Earnings vs. Estimates